Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carfilzomib - Onyx Pharmaceuticals

Drug Profile

Carfilzomib - Onyx Pharmaceuticals

Alternative Names: Kyprolis; ONO-7057; PR-171

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Proteolix
  • Developer AbbVie; Amgen; Dana-Farber Cancer Institute; Genentech; GSK; Janssen Biotech; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California at San Francisco; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Waldenstrom's macroglobulinaemia
  • Phase II Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma
  • Phase I/II Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Small cell lung cancer; Solid tumours
  • No development reported Leukaemia; Lymphoid leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Systemic lupus erythematosus

Most Recent Events

  • 12 Apr 2024 Amgen and Arbeitsgemeinschaft medikamentoese Tumortherapie completes a phase II trial in Multiple myeloma (Combination therapy, First line therapy) in Austria and Germany (NCT02891811) (EudraCT2016-000475-24)
  • 07 Nov 2023 Stanford University and Amgen completes a phase-I trial in Solid Tumours and Leukaemia (In infants, children, Adolescents, In adults, Second-line therapy or greater)in Canada and USA (NCT02512926)
  • 30 Oct 2023 Oncotherapeutics and Onyx terminates a phase II trial for Multiple myeloma (Second-line therapy or greater) in USA due to the difficulties to enroll patients (NCT02294357)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top